14 March 2019
China will strengthen management and supervision of vaccines to ensure their safety, the country’s top drug regulator said Monday.
Chinese lawmakers have finished their first reading of a draft law on vaccine management, and solicited public opinions, Jiao Hong, head of the National Medical Products Administration, told a press conference on the sidelines of the annual legislative session.
China’s vaccines are generally safe, Jiao said, adding that the development of a vaccine management mechanism with long-term effects is underway.
Vaccine-producing companies should build a sound quality management system and product safety tracing and risk reporting mechanisms.
Provincial drug regulators should enhance on-site checks on vaccine producers while the national administration will strengthen random checks, she said.
China will develop and train national and provincial professional inspectors to enhance supervision capabilities, she added.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024